|
ISOC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.21664916924647E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.53654866608122E-13 |
| Normal-vs-Stage2 |
8.542200E-03 |
| Normal-vs-Stage3 |
1.54399999999777E-05 |
| Normal-vs-Stage4 |
5.9778999999982E-05 |
| Stage1-vs-Stage2 |
1.020210E-01 |
| Stage1-vs-Stage3 |
4.774000E-02 |
| Stage1-vs-Stage4 |
2.271400E-01 |
| Stage2-vs-Stage3 |
8.270200E-01 |
| Stage2-vs-Stage4 |
6.776200E-01 |
| Stage3-vs-Stage4 |
7.661600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.51640938589526E-12 |
| Normal-vs-AfricanAmerican |
2.717300E-03 |
| Normal-vs-Asian |
2.00699999952647E-07 |
| Caucasian-vs-AfricanAmerican |
5.351600E-01 |
| Caucasian-vs-Asian |
5.039800E-01 |
| AfricanAmerican-vs-Asian |
9.173200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.33740000021854E-07 |
| Normal-vs-Female |
1.6180390360887E-12 |
| Male-vs-Female |
4.326800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.1076473899484E-12 |
| Normal-vs-Age(41-60Yrs) |
1.09789999314103E-09 |
| Normal-vs-Age(61-80Yrs) |
2.903500E-03 |
| Normal-vs-Age(81-100Yrs) |
3.031500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.884500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.791500E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.695000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.499900E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.527000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.032400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.245600E-01 |
| Classical-VS-Follicular |
2.11820000428631E-08 |
| Classical-VS-Other |
5.103800E-01 |
| Classical-VS-Normal |
1.62569957495862E-12 |
| Tall-VS-Follicular |
2.498600E-03 |
| Tall-VS-Other |
5.956800E-01 |
| Tall-VS-Normal |
1.79506999999912E-05 |
| Follicular-VS-Other |
2.640200E-01 |
| Follicular-VS-Normal |
1.653840E-01 |
| Other-VS-Normal |
1.812760E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.33110000000158E-06 |
| Normal-vs-N1 |
8.4010999999995E-05 |
| N0-vs-N1 |
2.655800E-01 |
|
|
